Amundi Has $213.04 Million Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• Amundi has reduced its stake in Edwards Lifesciences Corporation by 12.1%, now holding 2,919,186 shares valued at approximately $213.04 million.
• Analysts have upgraded their target prices for Edwards Lifesciences, with Deutsche Bank raising its target to $94.00, indicating a consensus rating of Moderate Buy and an average price target of $85.90.
• In recent insider activity, Larry L. Wood, an executive at Edwards Lifesciences, sold 8,950 shares at an average price of $78.06, indicating a significant change in ownership dynamics among company insiders.

Amundi decreased its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 12.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,919,186 shares of the medical research company's stock after selling 402,011 shares during the period. Amundi owned approximately 0.50% of Edwards Lifesciences worth $213,042,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its position in Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after acquiring an additional 145 shares during the period. Dynamic Advisor Solutions LLC grew its position in Edwards Lifesciences by 2.4% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock valued at $1,124,000 after buying an additional 370 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Edwards Lifesciences by 13.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock valued at $5,582,000 after buying an additional 9,188 shares during the period. United Asset Strategies Inc. raised its position in shares of Edwards Lifesciences by 10.4% during the 1st quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company's stock worth $13,450,000 after buying an additional 17,412 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 390.7% in the first quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company's stock valued at $633,000 after acquiring an additional 7,013 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft lifted their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Argus upgraded Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Barclays raised their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, July 25th. Citigroup reissued a "buy" rating and issued a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Finally, Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $86.45.

Insiders Place Their Bets

In related news, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider directly owned 206,900 shares of the company's stock, valued at approximately $15,565,087. The trade was a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,014 shares of company stock worth $1,698,844. 0.34% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Down 1.5%

Shares of NYSE:EW traded down $1.18 during trading on Wednesday, hitting $78.62. 876,623 shares of the company's stock were exchanged, compared to its average volume of 4,417,050. The firm has a 50-day moving average price of $78.86 and a two-hundred day moving average price of $75.29. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The firm has a market cap of $46.16 billion, a P/E ratio of 11.31, a PEG ratio of 3.87 and a beta of 1.07. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.